Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Arthritis & Rheumatism

• Publication date

  1999-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-XPMID 10616012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series

  1999cited by this paper
• Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.

  1999cited by this paper
• Intrapulmonary shunting in primary pulmonary hypertension: an observation in two patients treated with epoprostenol sodium.

  1998cited by this paper
• The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.

  1998cited by this paper
• Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

  1998cited by this paper
• Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group.

  1997cited by this paper
• Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension

  1997cited by this paper
• Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.

  1997cited by this paper
• Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension.

  1996cited by this paper
• Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension

  1996cited by this paper
• Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma--a pilot study.

  1996cited by this paper
• Prevalence of pulmonary hypertension in limited and diffuse scleroderma.

  1996cited by this paper
• Scleroderma. Clinical problems. The lungs.

  1996cited by this paper
• Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients.

  1996cited by this paper
• CLINICAL PROBLEMS: The Lungs

  1996cited by this paper
• Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

  1995cited by this paper
• Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin

  1994cited by this paper
• Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases.

  1994cited by this paper
• Lung Disease in Systemic Sclerosis (Scleroderma)

  1993cited by this paper
• Primary pulmonary hypertension.

  1993cited by this paper
• Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease.

  1992cited by this paper
• Mortality in systemic sclerosis (scleroderma).

  1992cited by this paper
• Adenosine as a Vasodilator in Primary Pulmonary Hypertension

  1991cited by this paper
• Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease.

  1991cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Predictors of survival in systemic sclerosis (scleroderma).

  1991cited by this paper
• The pulmonary pathologic manifestations of the CREST syndrome.

  1990cited by this paper
• Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome.

  1990cited by this paper
• Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.

  1990cited by this paper
• Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

  1990cited by this paper
• Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial

  1990cited by this paper
• Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

  1988cited by this paper
• High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

  1987cited by this paper
• Acute hemodynamic effects of ketanserin in pulmonary hypertension secondary to systemic sclerosis.

  1987cited by this paper
• Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards.

  1985cited by this paper

• Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension

  2023cites this paper
• Pulmonary Hypertension in Scleroderma- Evaluation and Management.

  2022cites this paper
• Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies

  2021cites this paper
• Intravenous prostacyclin-analogue therapy in pulmonary arterial hypertension - A review of the past, present and future.

  2021cites this paper
• Repositioned Drugs for COVID-19—the Impact on Multiple Organs

  2021cites this paper
• Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension

  2021influential citation
• Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment

  2020cites this paper
• Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis

  2020influential citation
• The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis

  2019cites this paper
• Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience

  2017cites this paper
• Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.

  2015cites this paper
• Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer

  2015cites this paper
• Predictive value of noninvasive evaluation by exercise echocardiography and BNP measurement for early identification of pulmonary arterial hypertension in patients affected by systemic sclerosis: 5 years follow-up

  2015cites this paper
• Variability in Hemodynamic Evaluation of Pulmonary Hypertension at Large Referral Centers

  2014cites this paper
• PREDICTIVE VALUE OF NONINVASIVE EVALUATION BY EXERCISE ECHOCARDIOGRAPHY AND BNP MEASUREMENT FOR EARLY IDENTIFICATION OF PULMONARY ARTERIAL HYPERTENSION IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS: 5 YEARS FOLLOW-UP

  2014cites this paper
• Hipertensión arterial pulmonar. Registro de un centro de referencia en Argentina

  2014cites this paper
• Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center

  2013cites this paper
• Diagnóstico y tratamiento de la hipertensión pulmonar en pacientes con esclerodermia

  2012cites this paper
• Pulmonary arterial hypertension in patients with HIV infection

  2012cites this paper
• Current Management of Primary Pulmonary Hypertension

  2012cites this paper
• Acute responses to inhalation of Iloprost in patients with pulmonary hypertension.

  2012cites this paper
• Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs.

  2011cites this paper
• Pulmonary arterial hypertension.

  2011cites this paper
• Pulmonary Hypertension and Cor Pulmonale

  2011cites this paper
• Pathobiology and Treatment of Pulmonary Hypertension in HIV Disease

  2011cites this paper
• Overview of current therapeutic approaches for pulmonary hypertension

  2011cites this paper
• Pulmonary hypertension in systemic sclerosis.

  2011cites this paper
• Adenosine for vasoreactivity testing in pulmonary hypertension: a head-to-head comparison with inhaled nitric oxide.

  2010cites this paper
• Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.

  2010cites this paper
• [Pulmonary vasoreactivity testing in diagnosis and prognosis of pulmonary hypertension].

  2010cites this paper
• Pharmacokinetic evaluation of continuous intravenous epoprostenol

  2010cites this paper
• ACCF/AHA Expert Conseusus Document

  2009cites this paper
• Reassessing Patients Over Time : How To Follow Patients on Treatment

  2009cites this paper
• Epoprostenol in pulmonary arterial hypertension.

  2009cites this paper
• Epoprostenol in pulmonary arterial hypertension

  2009cites this paper
• Connective Tissue Disease Associated Pulmonary Hypertension

  2008cites this paper
• Connective Tissue Diseases and the Heart

  2007cites this paper
• Epidemiology of pulmonary arterial hypertension.

  2007cites this paper
• chapter 57 – Pulmonary Arterial Hypertension

  2006cites this paper
• Associated With Connective Tissue Disease Treprostinil, a Prostacyclin Analogue, in Pulmonary Arterial Hypertension

  2006cites this paper
• Pulmonary arterial hypertension.

  2006cites this paper
• Noninfectious Pulmonary Complications of HIV

  2006cites this paper
• Hypertension artérielle pulmonaire associée aux connectivites

  2006cites this paper
• Chapter 67 – Pulmonary Involvement in Rheumatoid Disorders of Childhood

  2006cites this paper
• Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost

  2005cites this paper
• Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis.

  2004cites this paper
• [Scleroderma].

  2004cites this paper
• Pulmonary Arterial Hypertension in Systemic Sclerosis

  2004cites this paper
• Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.

  2004cites this paper
• Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.

  2003cites this paper
• Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.

  2003cites this paper
• Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.

  2003cites this paper
• Scleroderma and pulmonary hypertension

  2003cites this paper
• Pulmonary Hypertension in the Collagen Vascular Diseases

  2003cites this paper
• Pulmonary hypertension: Work in progress

  2003cites this paper
• [Isolated pulmonary hypertension in overlap syndrome: successful treatment by methylprednisolone pulse therapy].

  2003cites this paper
• HIV-associated pulmonary hypertension: diagnosis and treatment.

  2003cites this paper
• The Encyclopedia of Arthritis

  2003cites this paper
• Targeting mediators of vascular injury in scleroderma.

  2002cites this paper
• Management of systemic sclerosis.

  2002cites this paper
• New treatments for pulmonary arterial hypertension.

  2002cites this paper
• Life-threatening complications of systemic sclerosis.

  2002cites this paper
• Pulmonary hypertension in systemic sclerosis: bete noire no more?

  2002cites this paper
• Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?

  2002cites this paper
• Medikamentöse Behandlung von Patienten mit chronischer Pulmonaler Hypertonie

  2002cites this paper
• Current treatment options in systemic Sclerosis (Scleroderma).

  2002cites this paper
• [Cardiovascular involvement in systemic sclerosis].

  2002cites this paper
• Pulmonary hypertension associated with connective tissue disease.

  2002cites this paper
• Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome.

  2002cites this paper
• Stem cell transplantation: limits and hopes

  2001cites this paper
• Recognition and Management of Scleroderma in Children

  2001cites this paper
• Comment traiter une sclérodermie en 2001

  2001cites this paper
• Juvenile systemic scleroderma

  2001cites this paper
• Therapie der schweren pulmonalen Hypertonie mit Prostazyklin und Iloprost

  2001cites this paper
• Secondary pulmonary hypertension

  2001cites this paper
• Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

  2001cites this paper
• Treatment of Systemic Sclerosis

  2001cites this paper
• Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.

  2001cites this paper
• Treating systemic sclerosis in 2001.

  2001cites this paper
• Development of agents for the treatment of systemic sclerosis

  2001cites this paper
• [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].

  2001cites this paper
• Do we need controlled clinical trials in pulmonary arterial hypertension?

  2001cites this paper
• Raynaud's phenomenon, scleroderma, overlap syndromes, and other fibrosing syndromes.

  2000cites this paper
• Diffuse and limited cutaneous systemic scleroderma

  2000cites this paper
• Can We Improve Outcome in Systemic Sclerosis ?

  2000cites this paper
• IV epoprostenol for systemic sclerosis.

  2000cites this paper
• Epoprostenol for Pulmonary Hypertension in Scleroderma

  2000cites this paper
• Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.

  2000cites this paper
• Mixed connective tissue disease

  2000cites this paper
• Esclerose sistêmica difusa com hipertensão pulmonar isolada: relato de caso

  2000cites this paper
• Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.

  2000cites this paper
• Autoantibodies in systemic sclerosis.

  1996cites this paper